Aquestive Therapeutics Inc. (AQST) is scheduled to present multiple presentations highlighting results from the investigational use of its product candidate Anaphylm sublingual film in the treatment of severe allergic reactions, including anaphylaxis, at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting on November 7, 2025.
Anaphylm sublingual film, the company's lead asset, is the first and only non-device-based, orally delivered epinephrine product candidate for the proposed treatment of anaphylaxis, a rapid-onset, life-threatening allergic reaction requiring immediate intervention.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.